Candel Therapeutics, Inc.

Candel Therapeutics announces positive phase 3 trial results for CAN-2409 in localized prostate cancer, to be presented at ASCO 2025.
Quiver AI Summary
Candel Therapeutics, Inc. announced that it will present positive results from its phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) at the 2025 ASCO Annual Meeting. The trial aimed to evaluate the effectiveness of adding CAN-2409, combined with valacyclovir, to standard radiation therapy in improving disease-free survival (DFS) in patients with localized prostate cancer. Results showed a statistically significant improvement in DFS with a 30% reduction in the risk of cancer recurrence or death among patients treated with CAN-2409 compared to placebo. This trial is notable as it is the first in over 20 years to meet both primary and secondary endpoints for this condition. The trial results are expected to be pivotal for regulatory submissions and could provide transformative treatment options for patients with intermediate-to-high-risk localized prostate cancer.
Potential Positives
Results from the phase 3 clinical trial of CAN-2409 demonstrated a statistically significant improvement in disease-free survival (DFS), which may redefine treatment approaches for prostate cancer.
The trial met its primary and secondary endpoints, highlighting the effectiveness of CAN-2409 in reducing the risk of cancer recurrence.
This marks the first multicenter, randomized phase 3 trial in over 20 years to meet both primary and secondary endpoints in localized prostate cancer, emphasizing the significance of the findings.
The upcoming presentation at the ASCO Annual Meeting increases visibility and credibility for Candel Therapeutics and its innovative treatment approach.
Potential Negatives
The significant reliance on forward-looking statements may create uncertainty about the company's future, as actual outcomes could differ materially from expectations due to various risks and uncertainties.
The press release emphasizes a significant unmet medical need, suggesting that current treatment options may be inadequate, which could reflect negatively on the industry's effectiveness.
The mention of serious adverse events and treatment-related side effects, even if low, may raise concerns about the safety profile of CAN-2409 among potential users and investors.
FAQ
What is CAN-2409?
CAN-2409 (aglatimagene besadenovec) is Candel's advanced biological immunotherapy targeting localized prostate cancer to improve patient outcomes.
What are the results of the phase 3 trial for CAN-2409?
The trial showed a statistically significant improvement in disease-free survival compared to placebo, with a 30% reduction in recurrence risk.
When will the phase 3 trial results be presented?
The results will be presented at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025.
What is the primary endpoint of the CAN-2409 study?
The primary endpoint is the improvement in disease-free survival for patients receiving CAN-2409 plus radiation therapy.
What is the safety profile of CAN-2409?
CAN-2409 was generally well tolerated, with low incidence of severe adverse events, mostly mild flu-like symptoms reported.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CADL Insider Trading Activity
$CADL insiders have traded $CADL stock on the open market 22 times in the past 6 months. Of those trades, 2 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $CADL stock by insiders over the last 6 months:
PAUL B MANNING has made 2 purchases buying 1,250,000 shares for an estimated $7,500,000 and 0 sales.
PAUL PETER TAK (Chief Executive Officer) has made 0 purchases and 5 sales selling 117,895 shares for an estimated $782,958.
WILLIAM GARRETT NICHOLS (Chief Medical Officer) has made 0 purchases and 4 sales selling 80,478 shares for an estimated $624,569.
FRANCESCA BARONE (Chief Scientific Officer) has made 0 purchases and 4 sales selling 81,434 shares for an estimated $592,415.
SESHU TYAGARAJAN (Chief Technology Officer) has made 0 purchases and 4 sales selling 80,537 shares for an estimated $591,854.
CHARLES SCHOCH (See Remarks) has made 0 purchases and 3 sales selling 24,482 shares for an estimated $194,829.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CADL Hedge Fund Activity
We have seen 63 institutional investors add shares of $CADL stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
FMR LLC added 3,161,717 shares (+80.6%) to their portfolio in Q1 2025, for an estimated $17,863,701
BRAIDWELL LP removed 1,600,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $9,040,000
BLACKROCK, INC. added 579,823 shares (+49.0%) to their portfolio in Q1 2025, for an estimated $3,275,999
BAKER BROS. ADVISORS LP removed 544,794 shares (-18.3%) from their portfolio in Q1 2025, for an estimated $3,078,086
VANGUARD GROUP INC added 396,954 shares (+29.6%) to their portfolio in Q1 2025, for an estimated $2,242,790
CITADEL ADVISORS LLC removed 281,513 shares (-96.7%) from their portfolio in Q1 2025, for an estimated $1,590,548
MARSHALL WACE, LLP added 234,597 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,325,473
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CADL Analyst Ratings
Wall Street analysts have issued reports on $CADL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
H.C. Wainwright issued a "Buy" rating on 12/18/2024
To track analyst ratings and price targets for $CADL, check out Quiver Quantitative's $CADL forecast page.
Full Release
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company’s positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 30 to June 3, 2025.
The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of care radiation therapy could improve the proportion of patients achieving disease-free survival (DFS) among those pursuing curative treatment for newly diagnosed localized prostate cancer. The selection of DFS as the primary endpoint was a key element of the Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA).
The Company’s phase 3 clinical trial met its primary endpoint and secondary endpoints and demonstrated statistically significant improvement in DFS (p=0.0155) with a 30% reduction (HR 0.7) in the risk for prostate cancer recurrence or death due to any cause in patients who received CAN-2409 (n=496) compared to placebo (n=249). These results were initially announced in December 2024.
This is the first multicenter, randomized phase 3 trial in over 20 years to meet both primary and secondary endpoints in localized prostate cancer, potentially redefining treatment for intermediate-to-high-risk patients with prostate cancer who seek curative therapy to avoid cancer-related anxiety, salvage treatments associated with toxicity, and disease progression.
Glen Gejerman, M.D., MBA, Co-Director of Urologic Oncology at Hackensack Meridian Health, and one of the principal investigators of the study, stated: “The improvement in disease-free survival shown in this trial is not only statistically significant, but also clinically meaningful. The clinical findings were reinforced by tissue analysis: CAN-2409 led to a significantly higher rate of pathological clinical response in two-year biopsy samples compared to placebo, indicating that the cancer may have been eliminated at the microscopic level. Effective local control of prostate cancer is essential in patients who seek treatment with curative intent, as patients with positive prostate biopsies, two or more years after radical treatment, face a well-established higher risk of disease spreading within the pelvic region, developing distant metastases, and ultimately dying from prostate cancer during long-term follow-up.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel, said: “We are honored that our pivotal phase 3 CAN-2409 data will be presented at the ASCO Annual Meeting, reinforcing the strength of our previously announced results. There remains a significant unmet need among patients with intermediate-to-high-risk localized prostate cancer treated with curative intent, as approximately 30% experience disease recurrence following radical prostatectomy or radiotherapy. In the phase 3 study, the addition of CAN-2409 plus valacyclovir to standard of care radiotherapy significantly reduced the risk of tumor recurrence, with a generally favorable tolerability profile. The observed improvements in disease-free survival and pathological complete response rates underscore the promise of this innovative immunotherapy. As we continue advancing our regulatory preparations in anticipation of submitting a Biologics License Application for CAN-2409 in the fourth quarter of 2026, our focus remains on bringing this potentially transformative treatment to patients in need of better options.”
Key Findings to be Presented at ASCO 2025 Include
:
Primary Endpoint:
Statistically significant improvement in DFS for CAN-2409 plus radiation therapy (n=496) vs. radiation therapy alone (n=249) (p=0.0155; HR 0.7) in the intent to treat population.
Secondary & Exploratory Endpoints:
DFS improvement was observed both in patients receiving short term androgen deprivation therapy (ADT) and in patients not receiving ADT.
In an analysis that focused on prostate-specific outcomes (e.g., censored mortality due to other causes), CAN-2409 showed a highly significant effect (p=0.0046; HR 0.62) on prostate cancer-free survival.
Significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs. 58.6%, respectively; p=0.0164).
CAN-2409 induced 80.4% pathological complete responses in the two-year post-treatment biopsies compared to 63.6% observed in the control arm (p=0.0015).
Safety Profile:
CAN-2409 was generally well tolerated, with a low incidence of treatment related, serious adverse events in both arms (1.7% on CAN-2409 + standard of care vs. 2.2% on placebo + standard of care).
The most common CAN-2409-related adverse events were flu-like symptoms, fever, and chills, which were generally mild-to-moderate in severity and self-limited.
Presentation details:
CAN-2409 – Localized Prostate Cancer
Abstract Title:
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard-of-care external beam radiation therapy (EBRT) for newly diagnosed localized prostate cancer
Presenter:
Theodore DeWeese, M.D.*, the Francis Watt Baker, M.D., and Lenox D. Baker Jr., M.D., Dean of the Medical Faculty and CEO, Johns Hopkins Medicine
Session Title:
Oral Abstract Session – Genitourinary Cancer – Prostate, Testicular, and Penile
Session Date/Time:
Tuesday, June 3, 2025; 9:45 AM - 12:45 PM CT
Location:
Hall D1, McCormick Place Convention Center, Chicago, IL
* Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer. He has never received reimbursements, consulting fees, or any other fees from Candel, and he has no shares of common stock, options to purchase common stock or any other affiliation with Candel.
About CAN-2409
CAN-2409 (aglatimagene besadenovec), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with other therapeutic strategies.
Currently, Candel is evaluating CAN-2409 in non-small cell lung cancer (NSCLC) and borderline resectable pancreatic adenocarcinoma (PDAC) and has recently completed a successful phase 3 clinical trial in localized prostate cancer. CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, for the treatment of stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and for the treatment of localized primary prostate cancer. Candel’s pivotal phase 3 clinical trial in prostate cancer was conducted under a SPA agreed with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and recently completed successful phase 2a clinical trials in NSCLC and PDAC, and a pivotal phase 3 clinical trial in localized prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit:
www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; expectations regarding early biological readouts as predictor of clinical response; and expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact:
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Candel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025

The NASDAQ 100 Pre-Market Indicator is up 209.6 to 21,824.87. The total Pre-Market volume is currently 106,218,441 shares traded.
The following are the most active stocks for the pre-market session:
Broadcom Inc. (AVGO) is +31.15 at $211.81, with 3,374,092 shares traded. As reported by Zacks, the current mean recommendation for AVGO is in the "buy range".
NVIDIA Corporation (NVDA) is +2.45 at $139.79, with 2,863,154 shares traded. Over the last four weeks they have had 11 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2025. The consensus EPS forecast is $0.79. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.6612 at $31.28, with 2,339,357 shares traded. This represents a 533.22% increase from its 52 Week Low.
Candel Therapeutics, Inc. (CADL) is -3.35 at $6.45, with 2,229,538 shares traded. As reported by Zacks, the current mean recommendation for CADL is in the "strong buy range".
United Microelectronics Corporation (UMC) is -0.0108 at $6.39, with 1,987,605 shares traded., following a 52-week high recorded in prior regular session.
D-Wave Quantum Inc. (QBTS) is +0.19 at $4.10, with 1,978,466 shares traded. As reported by Zacks, the current mean recommendation for QBTS is in the "buy range".
ProShares UltraPro Short QQQ (SQQQ) is -0.78 at $28.79, with 1,661,354 shares traded. This represents a -.31% decrease from its 52 Week Low.
Palantir Technologies Inc. (PLTR) is +1.3599 at $74.56, with 1,590,686 shares traded. PLTR's current last sale is 201.51% of the target price of $37.
Mitsubishi UFJ Financial Group Inc (MUFG) is -0.12 at $12.05, with 1,350,468 shares traded. As reported by Zacks, the current mean recommendation for MUFG is in the "buy range".
Archer Aviation Inc. (ACHR) is +0.32 at $7.49, with 1,291,225 shares traded. As reported by Zacks, the current mean recommendation for ACHR is in the "buy range".
Alibaba Group Holding Limited (BABA) is -0.85 at $88.38, with 1,217,597 shares traded. As reported by Zacks, the current mean recommendation for BABA is in the "buy range".
Rubrik, Inc. (RBRK) is -2.2901 at $71.90, with 1,211,006 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2025. The consensus EPS forecast is $-0.8. , following a 52-week high recorded in prior regular session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Dec 13, 2024 : AVGO, NVDA, TSLL, CADL, UMC, QBTS, SQQQ, PLTR, MUFG, ACHR, BABA, RBRK

(RTTNews) - Candel Therapeutics, Inc. (CADL) announced the pricing of an underwritten public offering of 10,000,001 shares at $6 per share and pre-funded warrants to purchase up to an aggregate of 3.333 million shares at $5.99 per pre-funded warrant to purchase one share.
The gross proceeds from the offering are expected to be around $80 million. The company intends to use the net proceeds to continue the development of its product candidates and for general corporate purposes.
The offering is expected to be closed on or about December 16.
In addition, Candel has granted the underwriters a 30-day option to purchase up to 2 million additional shares at the public offering price.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Candel Therapeutics Prices Public Offering Of $80 Mln Of Shares

The NASDAQ 100 Pre-Market Indicator is up 116.55 to 21,484.73. The total Pre-Market volume is currently 144,926,925 shares traded.
The following are the most active stocks for the pre-market session:
Candel Therapeutics, Inc. (CADL) is +6.58 at $11.19, with 23,372,349 shares traded. As reported by Zacks, the current mean recommendation for CADL is in the "strong buy range".
Rezolve AI Limited (RZLV) is +0.5008 at $2.43, with 19,455,292 shares traded. As reported by Zacks, the current mean recommendation for RZLV is in the "strong buy range".
Silexion Therapeutics Corp (SLXN) is +0.35 at $3.07, with 5,671,432 shares traded. As reported by Zacks, the current mean recommendation for SLXN is in the "strong buy range".
Alphabet Inc. (GOOGL) is +0.42 at $185.59, with 5,026,732 shares traded. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Quantum-Si Incorporated (QSI) is +0.5498 at $2.81, with 4,977,621 shares traded. QSI's current last sale is 86.46% of the target price of $3.25.
Super Micro Computer, Inc. (SMCI) is -2.12 at $38.42, with 4,082,982 shares traded. SMCI's current last sale is 93.14% of the target price of $41.25.
D-Wave Quantum Inc. (QBTS) is +0.34 at $5.02, with 3,986,365 shares traded. As reported by Zacks, the current mean recommendation for QBTS is in the "buy range".
Macy's Inc (M) is -1.79 at $14.93, with 1,623,068 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Oct 2024. The consensus EPS forecast is $0.07. M's current last sale is 87.82% of the target price of $17.
Transocean Ltd. (RIG) is unchanged at $3.98, with 1,617,995 shares traded. RIG's current last sale is 66.33% of the target price of $6.
BigBear.ai, Inc. (BBAI) is -0.07 at $3.04, with 1,366,928 shares traded. As reported by Zacks, the current mean recommendation for BBAI is in the "buy range".
Lloyds Banking Group Plc (LYG) is +0.12 at $2.81, with 1,058,582 shares traded. LYG's current last sale is 102.18% of the target price of $2.75.
Joby Aviation, Inc. (JOBY) is -0.52 at $8.02, with 934,602 shares traded. JOBY's current last sale is 94.35% of the target price of $8.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Dec 11, 2024 : CADL, RZLV, SLXN, GOOGL, QSI, SMCI, QBTS, M, RIG, BBAI, LYG, JOBY

(RTTNews) - Candel Therapeutics Inc. (CADL) announced positive overall survival data from its phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate, plus valacyclovir (prodrug), together with standard of care immune checkpoint inhibitor or ICI therapy in patients with Stage III/IV non-small cell lung cancer or NSCLC inadequately responding to ICI (anti-PD-(L)1) therapy.
The data will be presented at the 2024 American Society of Clinical Oncology Annual Meeting, to be held in Chicago, May 31 to June 4, 2024, the company said.
CADL closed Thursday's regular trading at $10.69 up $0.11 or 1.04%. In the after-hours trading the stock further gained $3.97 or 37.14%.
The company noted that Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population.
The company noted that CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic and memory T cells associated with subsequent prolonged survival, and a beneficial effect on both injected and uninjected tumors (abscopal response).
As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile, the company said.
Previously, the Company received FDA Fast Track Designation for CAN-2409 in NSCLC and pancreatic cancer as well as orphan drug designation in pancreatic cancer.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Candel Therapeutics' CAN-2409 Enhances NSCLC Survival In Phase 2 Trial; Stock Surges

Candel Therapeutics, Inc.’s CADL shares skyrocketed 280.9% on Apr 5, after the company announced positive interim data from the phase II study evaluating its lead candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).
The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notable improvements in estimated median overall survival of 28.8 months compared with only 12.5 months in the control group in borderline resectable PDAC.
Patients treated with CAN-2409 had a survival rate of 71.4% versus only 16.7% in the control group after chemoradiation at 24 months of treatment. Moreover, the survival rate was 47.6% for patients treated with CAN-2409 compared with a mere 16.7% in the control group at 36 months.
Per the company, adding the CAN-2409 regimen to SoC was generally well tolerated while no new safety signals were observed. No cases of pancreatitis and dose-limiting toxicities were reported either.
Shares of Candel have skyrocketed 335.4% year to date compared with the industry’s growth of 1.5%.
Image Source: Zacks Investment Research
The above-mentioned survival data were updated with eight months of further follow-up since the first analysis, which was presented in 2023 at the annual meeting of the Society for Immunotherapy.
The FDA granted Fast Track designation to CAN-2409 plus prodrug (valacyclovir) for the treatment of PDAC in December 2023.
If successfully developed and a potential approval for CAN-2409 could present a significant commercial opportunity for Candel, given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, there remains a high unmet medical need for effective new treatments for PDAC.
Apart from pancreatic cancer, CADL expects key data readouts for CAN-2409 in non-small cell lung cancer later in the second quarter of 2024, while top-line data in prostate cancer is expected in the fourth quarter of 2024.
In the absence of a marketed product, the successful development of its pipeline candidates remains the key focus for this clinical-stage biopharmaceutical company.
Zacks Rank & Stocks to Consider
Candel currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are ADMA Biologics, Inc. ADMA, Ligand Pharmaceuticals Incorporated LGND and ANI Pharmaceuticals, Inc. ANIP, each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 38.9%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 9.2%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have rallied 23.2%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

Health care stocks were leaning higher pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) flat recently.
Nutex Health (NUTX) shares slid more than 8% after the company said it would implement a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
Candel Therapeutics (CADL) shares rose more than 14% in premarket activity Friday, extending gains a day after reporting positive interim data from a randomized phase 2 clinical study of non-metastatic pancreatic cancer.
Caribou Biosciences (CRBU) shares were up almost 4% after the company said federal regulators have cleared the biopharmaceutical company's application to begin phase 1 testing of its CB-010 cell therapy in patients with lupus nephritis and extrarenal lupus.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Health Care Sector Update for 04/05/2024: XLV, IBB, NUTX, CADL, CRBU

The NASDAQ 100 Pre-Market Indicator is up 91.74 to 17,970.52. The total Pre-Market volume is currently 59,707,673 shares traded.
The following are the most active stocks for the pre-market session:
Candel Therapeutics, Inc. (CADL) is +1.1 at $7.50, with 7,671,125 shares traded., following a 52-week high recorded in prior regular session.
GCT Semiconductor Holding, Inc. (GCTS) is +5.93 at $11.66, with 4,425,611 shares traded.
ProShares UltraPro Short QQQ (SQQQ) is -0.11 at $11.01, with 3,236,299 shares traded. This represents a 9.55% increase from its 52 Week Low.
Protara Therapeutics, Inc. (TARA) is +0.83 at $4.85, with 1,837,312 shares traded. As reported by Zacks, the current mean recommendation for TARA is in the "strong buy range".
ProShares UltraPro QQQ (TQQQ) is +0.6102 at $58.43, with 1,678,300 shares traded. This represents a 132.14% increase from its 52 Week Low.
ShockWave Medical, Inc. (SWAV) is +5.11 at $325.10, with 1,515,821 shares traded. As reported by Zacks, the current mean recommendation for SWAV is in the "buy range".
iShares Bitcoin Trust (IBIT) is -0.98 at $38.10, with 1,305,679 shares traded. This represents a 73.02% increase from its 52 Week Low.
NIO Inc. (NIO) is +0.03 at $4.53, with 528,288 shares traded. NIO's current last sale is 66.13% of the target price of $6.85.
Palantir Technologies Inc. (PLTR) is +0.17 at $22.65, with 509,257 shares traded. PLTR's current last sale is 113.25% of the target price of $20.
NuScale Power Corporation (SMR) is +0.27 at $6.43, with 344,444 shares traded. SMR's current last sale is 80.38% of the target price of $8.
Ford Motor Company (F) is +0.11 at $13.32, with 174,068 shares traded. F's current last sale is 102.46% of the target price of $13.
Carnival Corporation (CCL) is +0.11 at $15.17, with 164,220 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Aug 2024. The consensus EPS forecast is $1.08. As reported by Zacks, the current mean recommendation for CCL is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Apr 5, 2024 : CADL, GCTS, SQQQ, TARA, TQQQ, SWAV, IBIT, NIO, PLTR, SMR, F, CCL

The NASDAQ 100 Pre-Market Indicator is up 108.21 to 18,268.4. The total Pre-Market volume is currently 53,301,304 shares traded.
The following are the most active stocks for the pre-market session:
HWH International Inc. (HWH) is +0.8 at $2.37, with 7,642,819 shares traded.
Tevogen Bio Holdings Inc. (TVGN) is +2.4101 at $5.03, with 6,775,847 shares traded., following a 52-week high recorded in prior regular session.
Candel Therapeutics, Inc. (CADL) is +0.44 at $2.12, with 2,834,304 shares traded. As reported by Zacks, the current mean recommendation for CADL is in the "strong buy range".
Tilray Brands, Inc. (TLRY) is +0.0501 at $2.90, with 2,713,522 shares traded.TLRY is scheduled to provide an earnings report on 4/9/2024, for the fiscal quarter ending Feb2024. The consensus earnings per share forecast is -0.04 per share, which represents a -4 percent increase over the EPS one Year Ago
ProShares UltraPro Short QQQ (SQQQ) is -0.14 at $10.48, with 1,941,739 shares traded. This represents a 4.28% increase from its 52 Week Low.
Intuitive Machines, Inc. (LUNR) is +0.42 at $6.40, with 1,727,722 shares traded. As reported by Zacks, the current mean recommendation for LUNR is in the "strong buy range".
Palantir Technologies Inc. (PLTR) is +0.86 at $23.56, with 1,721,533 shares traded. PLTR's current last sale is 117.8% of the target price of $20.
RELX PLC (RELX) is -0.32 at $41.85, with 804,261 shares traded. As reported by Zacks, the current mean recommendation for RELX is in the "buy range".
NIO Inc. (NIO) is +0.04 at $4.53, with 509,198 shares traded. NIO's current last sale is 66.13% of the target price of $6.85.
Borr Drilling Limited (BORR) is -0.31 at $5.95, with 345,671 shares traded. As reported by Zacks, the current mean recommendation for BORR is in the "buy range".
Ford Motor Company (F) is +0.2201 at $13.87, with 319,386 shares traded. F's current last sale is 106.69% of the target price of $13.
NuScale Power Corporation (SMR) is -0.17 at $6.27, with 316,327 shares traded. SMR's current last sale is 78.38% of the target price of $8.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.